{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:53:39Z","timestamp":1787165619280,"version":"build-2736575974"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,10,15]],"date-time":"2009-10-15T00:00:00Z","timestamp":1255564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,10,15]],"date-time":"2009-10-15T00:00:00Z","timestamp":1255564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatologica"],"abstract":"<jats:p>Halogenated oxyquinolines have a pronounced therapeutic effect in acrodermatitis enteropathica. Since 1966, however, ocular and neurological side effects have been reported at the high doses required to obtain a clinical effect. We describe a patient in whom we followed the concentration of chlorquinaldol (5,7-dichloro-8-hydroxy-2-methylquinoline, Sterosan\u00ae) in plasma. The improvement in the skin condition was related to the dose; at a plasma concentration of 0.8\u20131.1 mg% the status was satisfactory. The half-life after ingestion of 300 mg Sterosan was calculated to be about 7 h. At a dosage of 300 mg every 8th hour a steady-state level of around 0.8-1 mg% was attained. We do not know the relationship between plasma levels and therapeutic and toxic effects. An answer to this question could be obtained by following up several cases on long-term treatment.<\/jats:p>","DOI":"10.1159\/000251468","type":"journal-article","created":{"date-parts":[[2009,10,21]],"date-time":"2009-10-21T09:05:16Z","timestamp":1256115916000},"page":"29-38","source":"Crossref","is-referenced-by-count":3,"title":["Determination of Oxyquinoline Concentrations in Plasma in a Patient Treated for Acrodermatitis enteropathica \u2013 an Aid in Therapeutic Control"],"prefix":"10.1159","author":[{"given":"\u00d6.","family":"H\u00e4germark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Wahlberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Germanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2009,10,15]]},"container-title":["Dermatologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/251468","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000251468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:49:31Z","timestamp":1777542571000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000251468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,15]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000251468","archive":["Portico"],"relation":{},"ISSN":["0011-9075","2571-7197"],"issn-type":[{"value":"0011-9075","type":"print"},{"value":"2571-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,15]]}}}